180 related articles for article (PubMed ID: 38271892)
1. Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond.
Andreakos E;
Semin Immunol; 2024 Mar; 72():101863. PubMed ID: 38271892
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
3. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
4. Type I and III interferon responses in SARS-CoV-2 infection.
Kim YM; Shin EC
Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
[TBL] [Abstract][Full Text] [Related]
5. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
7. Roles of Type I and III Interferons in COVID-19.
Choi H; Shin EC
Yonsei Med J; 2021 May; 62(5):381-390. PubMed ID: 33908208
[TBL] [Abstract][Full Text] [Related]
8. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
9. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
[TBL] [Abstract][Full Text] [Related]
10. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
[TBL] [Abstract][Full Text] [Related]
12. Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes.
Feng E; Balint E; Poznanski SM; Ashkar AA; Loeb M
Cells; 2021 Mar; 10(3):. PubMed ID: 33806810
[TBL] [Abstract][Full Text] [Related]
13. USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING.
Karlowitz R; Stanifer ML; Roedig J; Andrieux G; Bojkova D; Bechtel M; Smith S; Kowald L; Schubert R; Boerries M; Cinatl J; Boulant S; van Wijk SJL
Cell Death Dis; 2022 Aug; 13(8):684. PubMed ID: 35933402
[TBL] [Abstract][Full Text] [Related]
14. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.
Chiale C; Greene TT; Zuniga EI
Immunol Rev; 2022 Aug; 309(1):12-24. PubMed ID: 35775361
[TBL] [Abstract][Full Text] [Related]
15. Human genetics of SARS-CoV-2 infection and critical COVID-19.
Mogensen TH
Clin Microbiol Infect; 2022 Nov; 28(11):1417-1421. PubMed ID: 35218979
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases.
Tovo PA; Garazzino S; Daprà V; Pruccoli G; Calvi C; Mignone F; Alliaudi C; Denina M; Scolfaro C; Zoppo M; Licciardi F; Ramenghi U; Galliano I; Bergallo M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299101
[TBL] [Abstract][Full Text] [Related]
18. Interferon-lambda: New role in intestinal symptoms of COVID-19.
Pan YY; Wang LC; Yang F; Yu M
World J Gastroenterol; 2023 Apr; 29(13):1942-1954. PubMed ID: 37155525
[TBL] [Abstract][Full Text] [Related]
19. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces.
Stanifer ML; Guo C; Doldan P; Boulant S
Front Immunol; 2020; 11():608645. PubMed ID: 33362795
[TBL] [Abstract][Full Text] [Related]
20. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.
Galani IE; Rovina N; Lampropoulou V; Triantafyllia V; Manioudaki M; Pavlos E; Koukaki E; Fragkou PC; Panou V; Rapti V; Koltsida O; Mentis A; Koulouris N; Tsiodras S; Koutsoukou A; Andreakos E
Nat Immunol; 2021 Jan; 22(1):32-40. PubMed ID: 33277638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
